Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jun 16;2010(6):CD007801.
doi: 10.1002/14651858.CD007801.pub2.

Anticoagulant therapy for deep vein thrombosis (DVT) in pregnancy

Che Anuar Che Yaakob  1 , Abdulla Abu Dzarr, Ahmad Amir Ismail, Nik Ahmad Zuky Nik Lah, Jacqueline J Ho
Affiliations

Anticoagulant therapy for deep vein thrombosis (DVT) in pregnancy

Che Anuar Che Yaakob et al. Cochrane Database Syst Rev. .

Abstract

Background: Thromboembolic complications are much higher in pregnancy due to procoagulant changes. Heparin does not cross the placenta and the use of unfractionated heparin (UFH) is the current established practice in prophylaxis and treatment for thromboembolism in pregnancy.

Objectives: To compare the effectiveness of anticoagulant therapies for the treatment of deep vein thrombosis in pregnancy. The anticoagulant drugs included are UFH, low molecular weight heparin (LMWH) and warfarin.

Search strategy: We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (March 2010) and reference lists of retrieved studies.

Selection criteria: Randomised controlled trials comparing any combination of warfarin, UFH, LMWH and placebo in pregnant women.

Data collection and analysis: We used methods described in the Cochrane Handbooks for Systemic Reviews of Interventions for assessing the eligibility of studies identified by the search strategy. A minimum of two review authors independently assessed each study.

Main results: We did not identify any eligible studies for inclusion in the review.We identified three potential studies; after assessing eligibility, we excluded all three as they did not meet the prespecified inclusion criteria. One study compared LMWH and UFH in pregnant women with previous thromboembolic events and, for most of these women, anticoagulants were used as thromboprophylaxis. There were only three women who had a thromboembolic event during the current pregnancy and it was unclear whether the anticoagulant was used as therapy or prophylaxis. We excluded one study because it included only women undergoing caesarean birth. The third study was not a randomised trial.

Authors' conclusions: There is no evidence from randomised controlled trials on the effectiveness of anticoagulation for deep vein thrombosis in pregnancy. Further studies are required.

PubMed Disclaimer

Conflict of interest statement

None known.

Update of

References

References to studies excluded from this review

Burrows 2001 {published data only}
    1. Burrows RF, Gan ET, Gallus AS, Wallace EW, Burrows EA. A randomised double‐blind placebo controlled trial of low molecular weight heparin as prophylaxis in preventing venous thrombolic events after caesarean section: a pilot study. British Journal of Obstetrics and Gynaecology 2001;108:835‐9. - PubMed
Pettilä 1999 {published data only}
    1. Pettila V, Kaaja R, Leinonen P, Ekblad U, Kataja M, Ikhala E. Thromboprophylaxis with low molecular weight heparin (Dalteparin) in pregnancy. Thrombosis Research 1999;96:275‐82. - PubMed
    1. Pettila V, Leinonen P, Markkola A, Hiilesmaa V, Kaaja R. Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thrombosis and Haemostasis 2002;87(2):182‐6. - PubMed
Rodie 2002 {published data only}
    1. Rodie VA, Thomson AJ, Stewart FM, Quinn AJ, Walker ID, Greer IA. Low molecular weight heparin for the treatment of venous thromboembolism in pregnancy: a case series. BJOG: an international journal of obstetrics and gynaecology 2002;109:1020‐24. - PubMed

Additional references

Akl 2008
    1. Akl EA, Rohilla S, Barba M, Sperati F, Terrenato I, Muti P, et al. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Cochrane Database of Systematic Reviews 2008, Issue 1. [DOI: 10.1002/14651858.CD006466] - PubMed
Dager 2003
    1. Dager WE, White RH. Phamacotherapy of heparin‐induced thrombocytopenia. Expert Opinion on Pharmacotherapy 2003;4(6):919‐40. - PubMed
Dimitrakakis 2000
    1. Dimitrakaki C, Papageorgio P, Papageorgiou I, Antzaklis A, Sakarelou N, Michalas S. Absence of transplacental passage of the low molecular weight heparin enoxaparin. Haemostasis 2000;30:243‐8. - PubMed
Gates 2002
    1. Gates S, Brocklehurst P, Davis LJ. Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. Cochrane Database of Systematic Reviews 2002, Issue 2. [DOI: 10.1002/14651858.CD001689] - DOI - PubMed
Gouin‐Thibault 2005
    1. Gouin‐Thibault I, Pautus E, Siguret V. Safety profile of different low‐molecular weight heparins used at therapeutic dose. Drug Safety 2005;28(4):333‐49. - PubMed
Greer 2002
    1. Greer IA. Exploring the role of low‐molecular‐weight heparins in pregnancy. Seminars in Thrombosis and Hemostasis 2002;28 Suppl 3:25‐31. - PubMed
Higgins 2008
    1. Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008. Available from www.cochrane‐handbook.org.
Holmes 2005
    1. Holmes VA, Wallance JMW. Haemostasis in normal pregnancy: a balancing act?. Biochemical Society Transactions 2005;33(Pt 2):428‐32. - PubMed
RCOG 2007
    1. Royal College of Obstetricians and Gynaecologists. Thromboembolic disease in pregnancy and the puerperium: acute management. Green‐top Guideline no. 27. London: RCOG, 2007.
RevMan 2008 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
Turpie 2002
    1. Turpie AGG, Mason JA. Review of enoxaparin and its clinical applications in venous and arterial thromboembolism. Expert Opinion on Pharmacology 2002;3(5):575‐98. - PubMed
Van Dongen 2004
    1. Dongen CJ, Belt AGM, Prins MH, Lensing AWA. Fixed dose subcutaneous low molecular weight heparins versus adjusted dose unfractionated heparin for venous thromboembolism. Cochrane Database of Systematic Reviews 2004, Issue 4. [DOI: 10.1002/14651858.CD001100.pub2] - PubMed

Publication types

MeSH terms